Do you want to read an article? Please log in or register.
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Cardiovascular Risk and Diseases
Related content
Cardiovascular Risk and DiseasesFurther Publications
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial
JAMA Cardiol
Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Skaarup KG, Pareek M, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T
doi: 10.1001/jamacardio.2025.3460
COMMENTED
Cardiovascular Risk and Diseases
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D
doi: 10.1016/S2213-8587(24)00396-6
Cardiovascular Risk and Diseases
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
Lancet
Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, Plutzky J, Kushner RF, Colhoun HM, Hovingh GK, Stensen S, Weeke PE, Jeppesen OK, Bravo R, Wu CC, Komuro I, Santini F, Hjelmesæth J, Urina-Triana M, Buscemi S, Ryan DH
doi: 10.1016/S0140-6736(25)01375-3
Heart, Artery and Coronary Diseases
Preoperative Cardiovascular Risk and Postoperative Outcomes by Renin-Angiotensin System Inhibitor Use: A Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiol
Tang J, Pirracchio R, Cholley B, Joosten A, Birckener J, Falcone J, Charbonneau H, Delaporte A, Chen D, Gayat E, Legrand M
doi: 10.1001/jamacardio.2025.1920
Atrial Fibrillation
Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial
JAMA Cardiol
Metzner A, Willems S, Borof K, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Fabritz L, Gessler N, Goette A, Reissmann B, Schnabel RB, Schotten U, Zapf A, Rillig A, Kirchhof P
doi: 10.1001/jamacardio.2025.2374
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8
Myocardial InfarctionTherapy and Intervention
Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients with Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial
Circ Cardiovasc Interv
Rao SV, Brooks MM, D'Agostino HEA, Steg PG, Simon T, Aronow HD, Goldsweig AM, Malik S, Alsweiler C, Ho KK, Dehghani P, Caixeta A, Quraishi AR, Robinson S, Traverse JH, Siddiqi O, Fergusson DA, Potter BJ, Schulman-Marcus J, Keating FK, Carson JL, MINT Trial Investigators
doi: 10.1161/CIRCINTERVENTIONS.125.015249
Cardiovascular Risk and Diseases
Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors
Cardiovasc Diabetol
Zhang XR, Zhong WF, Liu RY, Huang JL, Fu JX, Gao J, Zhang PD, Liu D, Li ZH, He Y, Zhou H, Li Z
doi: 10.1186/s12933-025-02711-x
Cardiovascular Risk and DiseasesTherapy and Intervention
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial
Lancet
Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, Lee HC, Chang K, Park MW, Bae JW, Doh JH, Cho BR, Kim HY, Kim W, Kim U, Rha SW, Hong YJ, Lee HJ, Ahn SG, Kim DI, Cho JH, Her SH, Jeon DS, Han SH, Lee JB, Lee CW, Kang D, Lee JM, Park TK, Yang JH, Lee SY, Choi SH, Gwon HC, Song YB, Hahn JY, SMART-CHOICE 3 investigators
doi: 10.1016/S0140-6736(25)00449-0